Dr. Reddy’s Laboratories has launched bosutinib tablets in the United States, becoming the first company to introduce a generic version of Pfizer’s cancer drug Bosulif. The launch marks another important milestone in the Indian drugmaker’s efforts to expand its presence in the oncology segment.
Bosutinib is used in the treatment of chronic myeloid leukemia (CML), a blood cancer that affects white blood cells and bone marrow. The medicine is prescribed for adults with newly diagnosed Philadelphia chromosome-positive CML as well as patients whose disease has not responded to earlier therapies.
The launch follows approval from the US Food and Drug Administration (USFDA) and covers multiple dosage strengths of the drug. By introducing a generic alternative, Dr. Reddy’s aims to improve access to treatment while offering a more affordable option for patients in the US.
The product presents a significant commercial opportunity for the company. According to market data, Bosulif generated sales of around $721 million in the US during the 12 months ended April 2026. As the first generic entrant, Dr. Reddy’s is expected to benefit from limited competition during the initial phase of the launch.
The development is in line with the company’s strategy of focusing on complex generics and specialty products in regulated markets. Oncology remains one of the fastest-growing segments for pharmaceutical companies, driven by increasing demand for advanced cancer treatments and affordable alternatives.
Industry experts believe the launch could strengthen Dr. Reddy’s position in the US market, which remains a major revenue contributor for Indian pharmaceutical companies. Generic launches in niche and high-value therapy areas are increasingly becoming a key growth driver for the sector.
The latest addition also expands Dr. Reddy’s oncology portfolio, which includes a range of products targeting various forms of cancer. The company has been steadily investing in research, development and regulatory approvals to enhance its presence in specialised treatment categories.
The launch underscores the growing role of Indian pharmaceutical firms in supplying cost-effective medicines to global markets while expanding their footprint in complex therapeutic areas.
Also Read: US- Iran seal peace deal, signing this week
